Back to discover
Disease

Migraine, familial hemiplegic, 3

Late-stage therapeutic development

Also known as SCN1A familial or sporadic hemiplegic migraine, familial or sporadic hemiplegic migraine caused by mutation in SCN1A, migraine, familial hemiplegic, type 3, FHM3.

24
Clinical trials
1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2028.
Upcoming Milestones
Clinical Milestones14View all 14
Results posted 2
Results expected 5
Recently completed 4
Other updates 2
+6 more in the activity timeline below
Activity timeline14

Clinical trials

11 sponsors · 0 new · 5 completed in the last 12 months (net -2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age

Phase 3 · Recruiting · Pfizer

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Phase 3 · Recruiting · AbbVie

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Phase 3 · Recruiting · Pfizer

Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Phase 3 · Recruiting · Pfizer

A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study

Phase 4 · Recruiting · Mayo Clinic

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.

Phase 3 · Recruiting · AbbVie
Recruiting

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age

Phase 3 · Recruiting · Pfizer

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Phase 3 · Recruiting · AbbVie

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Phase 3 · Recruiting · Pfizer

Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Phase 3 · Recruiting · Pfizer

A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study

Phase 4 · Recruiting · Mayo Clinic

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.

Phase 3 · Recruiting · AbbVie
Recently completed

Safety and Efficacy of Zonisamide Versus Topiramate in Migraine

Phase 3 · Completed · Kafrelsheikh University

A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine

Phase 3 · Completed · AbbVie

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age

Phase 3 · Completed · Teva Branded Pharmaceutical Products R&D LLC

A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine

Phase 3 · Completed · AbbVie

A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)

Phase 3 · Completed · AbbVie

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])

Phase 3 · Completed · Amgen

Evidence coverage

8 treatments

How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.

High evidence coverage
88% · 29/33 eligible items incorporated

Largest gap: no meaningful change (2, trial-readability).

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SCN1A0.79

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Sodium channel protein type 1 subunit alphavia SCN1A0.79

Reference

Authoritative identity, definition & identifiers.

Synonyms

SCN1A familial or sporadic hemiplegic migraine, familial or sporadic hemiplegic migraine caused by mutation in SCN1A, migraine, familial hemiplegic, type 3, FHM3

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.